NCT01571557View on ClinicalTrials.gov

A Safety and Efficacy Study to Assess OZURDEX® in Patients With Macular Oedema Secondary to Retinal Vein Occlusion (RVO)

CompletedOBSERVATIONAL
Enrollment

573

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

March 31, 2014

Study Completion Date

June 30, 2014

Conditions
Macular EdemaRetinal Vein Occlusion
Interventions
DRUG

dexamethasone 700 ug intravitreal implant

dexamethasone 700 ug intravitreal implant administered according to standard of care.

Trial Locations (1)

Unknown

Berlin

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY